{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:52Z","timestamp":1787009032364,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012276","name":"Tillotts Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pseudomonas aeruginosa bloodstream infections (Pa-BSIs) are still a major cause of mortality in ICUs, posing many treatment uncertainties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective study analysed data from 14 Italian hospitals, including all consecutive adults developing Pa-BSI in ICU during 2021\u201322 and treated with antibiotics for at least 48\u2005h. The primary aim was to identify predictors of 30\u2005day mortality using Cox regression. Results were adjusted with inverse probability of treatment weighting (IPTW) and for immortal time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 170 patients were included. High-risk BSI (source: lung, intra-abdominal, CNS) occurred in 118 (69%) patients, and 54 (32%) had septic shock. In 37 (22%), 73 (43%), 12 (7%) and 48 (28%) the definitive backbone therapy was piperacillin\/tazobactam, carbapenems, colistin or new antipseudomonal cephalosporins (ceftolozane\/tazobactam, n\u200a=\u200a20; ceftazidime\/avibactam, n\u200a=\u200a22; cefiderocol, n\u200a=\u200a6), respectively. Moreover, 58 (34%) received a second drug as combination therapy. The incidence of 30\u2005day all-cause mortality was 27.6% (47 patients). By Cox regression, Charlson comorbidity index, neutropenia, septic shock and high-risk BSI were independent predictors of 30\u2005day mortality, while previous colonization by P. aeruginosa, use of antipseudomonal cephalosporins as definitive treatment, and combination therapy were shown to be protective. However, after IPTW adjustment, only the protective effect of antipseudomonal cephalosporins was confirmed (adjusted HR\u200a=\u200a0.27, 95% CI\u200a=\u200a0.10\u20130.69), but not for combination therapy. Hence, the treatment effect was calculated: antipseudomonal cephalosporins significantly reduced mortality risk [\u221217% (95% CI\u200a=\u200a\u22124% to \u221230%)], while combination therapy was beneficial only in the case of septic shock [\u221266% (95% CI\u200a=\u200a\u221244% to \u221288%].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In ICU, antipseudomonal cephalosporins may be the preferred target therapy for the treatment of Pa-BSI; in addition, initial combination therapy may be protective in the case of septic shock.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf080","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:26:22Z","timestamp":1741015582000},"page":"1342-1353","source":"Crossref","is-referenced-by-count":11,"title":["Antipseudomonal cephalosporins versus piperacillin\/tazobactam or carbapenems for the definitive antibiotic treatment of\n                    <i>Pseudomonas aeruginosa<\/i>\n                    bacteraemia: new kids on the ICU block?"],"prefix":"10.1093","volume":"80","author":[{"given":"Davide Fiore","family":"Bavaro","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan ,","place":["Italy"]},{"name":"Infectious Diseases Unit, IRCCS Humanitas Research Hospital , Via Manzoni 56, Rozzano, 20089 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Accurso","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone , 90127 Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin , 10124 Turin ,","place":["Italy"]},{"name":"Department of Infectious Diseases, Tufts University School of Medicine , Boston, MA 02111 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa , 16126 Genoa ,","place":["Italy"]},{"name":"Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino , 16126 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Schenone","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa , 16126 Genoa ,","place":["Italy"]},{"name":"Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino , 16126 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Diella","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan ,","place":["Italy"]},{"name":"Infectious Diseases Unit, IRCCS Humanitas Research Hospital , Via Manzoni 56, Rozzano, 20089 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Fasciana","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialities, University of Palermo , 90127 Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant\u2019Orsola Bologna , 40138 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa , 16126 Genoa ,","place":["Italy"]},{"name":"Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino , 16126 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mornese Pinna","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin , 10124 Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Pascale","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant\u2019Orsola Bologna , 40138 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giovannenze","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS , 00168 Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-5419","authenticated-orcid":false,"given":"Nicholas","family":"Geremia","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Unit of Infectious Diseases , Ospedale Dell\u2019Angelo, 30174 Venice ,","place":["Italy"]},{"name":"Department of Clinical Medicine, Unit of Infectious Diseases, \u2018SS. Giovanni e Paolo\u2019 Civilian Hospital , 30122 Venice ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Infectious Diseases Unit, ARNAS Garibaldi Hospital, University of Catania , 95122 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant\u2019Orsola Bologna , 40138 Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-0130","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin , 10124 Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL), University of Genoa , 16126 Genoa ,","place":["Italy"]},{"name":"Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino , 16126 Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan ,","place":["Italy"]},{"name":"Infectious Diseases Unit, IRCCS Humanitas Research Hospital , Via Manzoni 56, Rozzano, 20089 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2025050205520788000_dkaf080-B1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"key":"2025050205520788000_dkaf080-B2","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","article-title":"Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study","volume":"38","author":"Tabah","year":"2012","journal-title":"Intensive Care Med"},{"key":"2025050205520788000_dkaf080-B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"Suppl 2","key":"2025050205520788000_dkaf080-B4","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025050205520788000_dkaf080-B5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"2025050205520788000_dkaf080-B6","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/cc10114","article-title":"Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality","volume":"15","author":"Prowle","year":"2011","journal-title":"Crit Care"},{"key":"2025050205520788000_dkaf080-B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00134-017-5036-1","article-title":"Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM\/ESCMID\/WAAAR round table on multi-drug resistance","volume":"44","author":"De Waele","year":"2018","journal-title":"Intensive Care Med"},{"key":"2025050205520788000_dkaf080-B8","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/cid\/ciz668","article-title":"Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection: a multisite retrospective study","volume":"70","author":"Babich","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025050205520788000_dkaf080-B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13756-019-0520-8","article-title":"A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections","volume":"8","author":"Shi","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025050205520788000_dkaf080-B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025050205520788000_dkaf080-B11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2025050205520788000_dkaf080-B12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2334-12-308","article-title":"Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia","volume":"12","author":"Park","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2025050205520788000_dkaf080-B13","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/jac\/dkx315","article-title":"Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis","volume":"72","author":"Ripa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520788000_dkaf080-B14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520788000_dkaf080-B15","doi-asserted-by":"publisher","first-page":"105891","DOI":"10.1016\/j.ijantimicag.2020.105891","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications","volume":"55","author":"Maraolo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520788000_dkaf080-B16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025050205520788000_dkaf080-B17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/23744235.2020.1856921","article-title":"Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review","volume":"53","author":"Bavaro","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"2025050205520788000_dkaf080-B18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520788000_dkaf080-B19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"2025050205520788000_dkaf080-B20","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02452-1","article-title":"Incidence and resistance rates of Pseudomonas aeruginosa bloodstream infections in Switzerland: a nationwide surveillance study (2010\u20132022)","author":"Renggli","year":"2025","journal-title":"Infection"},{"key":"2025050205520788000_dkaf080-B21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025050205520788000_dkaf080-B22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2025050205520788000_dkaf080-B23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections, 1988","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"2025050205520788000_dkaf080-B24","article-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 13.1","author":"EUCAST","year":"2023"},{"key":"2025050205520788000_dkaf080-B25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025050205520788000_dkaf080-B26","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025050205520788000_dkaf080-B27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2025050205520788000_dkaf080-B28","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2025050205520788000_dkaf080-B29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2025050205520788000_dkaf080-B30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520788000_dkaf080-B31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","article-title":"Antimicrobial heteroresistance: an emerging field in need of clarity","volume":"28","author":"El-Halfawy","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2025050205520788000_dkaf080-B32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12879-015-1123-5","article-title":"Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis","volume":"15","author":"Raman","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025050205520788000_dkaf080-B33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.47102\/annals-acadmedsg.V43N11p526","article-title":"Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia","volume":"43","author":"Tan","year":"2014","journal-title":"Ann Acad Med Singap"},{"key":"2025050205520788000_dkaf080-B34","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10096-017-2907-x","article-title":"Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study","volume":"36","author":"Paulsson","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025050205520788000_dkaf080-B35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4212\/cjhp.v68i5.1485","article-title":"Outcomes in documented Pseudomonas aeruginosa bacteremia treated with intermittent IV infusion of ceftazidime, meropenem, or piperacillin-tazobactam: a retrospective study","volume":"68","author":"Kwee","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"2025050205520788000_dkaf080-B36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/1471-2334-14-489","article-title":"Treatment of bloodstream infections in ICUs","volume":"14","author":"Timsit","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025050205520788000_dkaf080-B37","doi-asserted-by":"publisher","first-page":"106517","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520788000_dkaf080-B38","doi-asserted-by":"publisher","first-page":"e0019423","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205520788000_dkaf080-B39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/14787210.2022.2071701","article-title":"Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol","volume":"20","author":"Canton","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025050205520788000_dkaf080-B40","doi-asserted-by":"publisher","first-page":"e0229221","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"Suppl 4","key":"2025050205520788000_dkaf080-B41","doi-asserted-by":"publisher","first-page":"S559","DOI":"10.1093\/clinids\/7.Supplement_4.S559","article-title":"Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations","volume":"7","author":"Allan","year":"1985","journal-title":"Rev Infect Dis"},{"key":"2025050205520788000_dkaf080-B42","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/CCM.0b013e3181e96b91","article-title":"A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic\/meta-regression study","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"2025050205520788000_dkaf080-B43","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/jac\/dkad215","article-title":"Loading dose plus continuous\/extended infusion versus intermittent bolus of \u03b2-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study","volume":"78","author":"Bavaro","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1342\/62417459\/dkaf080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1342\/62417459\/dkaf080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T05:52:16Z","timestamp":1746165136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1342\/8078947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,15]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf080","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,15]]}}}